Prostate Cancer Foundation’s goal is always to deliver the most cutting-edge treatments and information to families dealing with prostate cancer. As such, they have committed to updating the patient guide to reflect the very latest research and discoveries for patients.
This is our third round of updates for 2019. Changes include:
- Updated information on local treatments for recurrent prostate cancer
- Updated information on therapies for metastatic hormone-sensitive prostate cancer
- New FDA approval of darolutamide for non-metastatic CRPC
- New information about non-hormonal therapy options for select patients
- New information on the use of PARP inhibitors as an emerging therapy
- Updated recommendations on when to talk to your doctor about PSA screening
- Updated nutrition recommendations
Download an updated digital copy today and then be sure to provide feedback.
Stanford radiation oncologist prostate cancer expert Dr. Patrick Swift presents on the new advances on prostate cancer and its treatment. Watch the recording HERE
URO Today has published a collection of videos from the APCC 2019 conference. This informative collection of 60 short videos cover a wide range of prostate cancer topics. You can view the video collection on URO Today HERE
From Dr. Fabio’s blog post:
Over the last few years, we have seen tremendous activity in the area of molecular imaging for prostate cancer. Just about every day we have colleagues asking about the various PET/CT imaging tests – what is available? How do they compare? What are the parameters for successful imaging?
We are proud to have contributed to this body of knowledge. Our work regarding C11-Acetate PET/CT imaging in the recurrent PCa setting with relationship to PSA kinetics has been recently published – representing the largest single-site evaluation of a molecular imaging agent. A link to the publication and brief overview of PET/CT Imaging for Prostate Cancer follow for your review. We hope you find this review useful.
Read the entire article on drfabio.com HERE
Prostate cancer–specific positron emission tomography (pcPET) has been shown to detect sites of disease recurrence at serum prostate-specific antigen (PSA) levels that are lower than those levels detected by conventional imaging. Commonly used pcPET radiotracers in the setting of biochemical recurrence are reviewed including carbon 11/fludeoxyglucose 18 (F-18) choline, gallium 68/F-18 prostate-specific membrane antigen (PSMA), and F-18 fluciclovine.
Note that this article mentions C-11 acetate briefly but does not cover it. Phoenix Molecular Imaging is not shown on the map of imaging centers. Also, the study does not examine the significance of PSA doubling time, whereas it has been reported that short doubling time enhances detection with C11-Acetate even at very low PSA.
Read the entire article on sciencedirect.com HERE
The 2018 Genitourinary Cancers Symposium event featured groundbreaking research among members of the cancer care and research community who diagnose, treat, and study genitourinary malignancies.
Click on the below links to view conference proceedings on
Highlights and summary from the 24th Annual PCF Scientific Retreat on October 2017. Read the report here.
US Too Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer
- Presented by: Bayer
- Sponsored by: Dendreon and Jannsen Oncology
- In Kind Sponsor: Los Padres
- Guest Speakers:
- Dr. Edwin Morales – Urology Specialist, San Antonio
- Dr. Michael Liss – Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
- Dr. Vijay K. Gunuganti – Medical Oncologist at Texas Oncology
- Moderator: Dr. Juan A. Reyna – Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health
Watch the recording here
Dr. Mark Scholz participated in a tumor board session with a discussion of Prostate Cancer Cases at El Camino Hospital in November 2017.
- Robert Sinha, MD, Medical Director of Radiation Oncology
- Frank Lai, MD, Urological Oncologist/Robotic Surgeon, El Camino Hospital
- Steven Kurtzman, MD, Radiation Oncologist, Director of Prostate Brachytherapy, El Camino Hospital
- Shane Dormady, MD PhD, Medical Director of Oncology, El Camino Hospital
- Mark Scholz, MD, Medical Oncology, Director of Prostate Cancer Specialists, Founder of Prostate Cancer Research Institute
View the recording of the event here
A Short Course in Prostate Cancer – eBook
The purpose of this short eBook is to provide men facing prostate cancer with a lot of up-to-date information in a compact format.
The information and opinions provided in this book are not specific medical advice for any individual. It should not substitute for medical advice from a healthcare professional. The author is not a medical doctor. The reader is advised that any information or opinions expressed or implied in this book are those of a layman and should not be acted upon without the consent of a licensed physician. This book is not meant to be used, nor should it be used, to diagnose or treat any medical condition. For diagnosis or treatment of any medical problem, consult your own physician.
Download the pdf ebook here.